本帖最后由 老马 于 2013-3-13 13:43 编辑 5 m/ X J9 ?; F
% H' i4 Q2 h& z/ {. m" ~! I7 p" F8 r
健择（吉西他滨）+顺铂+阿瓦斯汀
5 H) _1 v7 h+ z4 l+ S Gemzar +Cisplatin + Avastin% U4 e* y# J9 q
http://annonc.oxfordjournals.org/content/21/9/1804.full, M2 X8 Q. |6 ]% {- K
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
3 q; M Z# c8 g( _. M, iPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. # X' \ T8 B% R$ `7 ^5 s
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 7 _/ @. ~0 D' x$ l9 {
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 241)
1 J* |* J* d; U1 d7 N华为网盘附件：' q: Y, \; i( r# F3 ?
【华为网盘】ava.JPG- P- a$ ]. ^+ d, M; Y5 J
|
显身卡
